Brigitte C. Widemann
Brigitte C. Widemann is a renowned oncologist and medical researcher specializing in the study and treatment of neurofibromatosis. She currently serves as the Chief of the Pediatric Oncology Branch at the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH).
Early Life and Education
Brigitte C. Widemann was born and raised in Germany. She completed her undergraduate studies in biology and chemistry before moving to the United States for her medical education. She earned her medical degree from the University of Pennsylvania School of Medicine.
Career
Following her graduation, Widemann completed her residency in pediatrics at the Children's Hospital of Philadelphia. She then pursued a fellowship in pediatric oncology at the National Cancer Institute.
In her role as the Chief of the Pediatric Oncology Branch at the NCI, Widemann leads a team of researchers and clinicians dedicated to improving the lives of children and young adults with cancer and genetic tumor predisposition syndromes. Her research primarily focuses on the development of new therapies for patients with neurofibromatosis type 1 (NF1), a genetic disorder that causes tumors to form on nerve tissue.
Research and Contributions
Widemann's research has led to significant advancements in the understanding and treatment of neurofibromatosis. She has been instrumental in the development of selumetinib, a drug that has shown promise in shrinking tumors in children with NF1. Her work has been published in numerous peer-reviewed medical journals and she is often invited to speak at international conferences on pediatric oncology and neurofibromatosis.
Awards and Recognition
Over the course of her career, Widemann has received numerous awards and recognition for her contributions to the field of pediatric oncology. These include the NIH Director's Award and the Distinguished Clinical Teacher Award from the NIH Clinical Center.
See Also
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
